Tests are scheduled to commence April 23rd for a malaria vaccine; the FDA has approved the first generic nasal spray for opioid overdose reversal; scientists have discovered a new broad-spectrum, arsenic-based antibiotic.
A malaria vaccine, which could potentially reduce the number of infections and related deaths, is due to be tested, according to STAT News. Concerns remain whether the benefits of the vaccine can be repeated outside clinical trials. The World Health Organization (WHO) designed a beta test for the vaccine, named RTS,S and developed by GlaxoSmithKline, that will start April 23. Malawi will be the first nation to incorporate the vaccine into immunization programs for children, while Kenya and Ghana are expected to follow. The beta test will allow WHO to decide whether RTS,S could be used effectively and whether the results from a phase 3 clinical trial, which showed a 40% decrease in malaria infections, can be replicated in a real-world setting.The FDA on Friday approved the first generic nasal spray version of naloxone (Narcan), which can reverse opioid overdoses, The New York Times reported. It has been sold in the United States as a nasal spray since 2016 and pharmacists have the ability to dispense the life-saving drug without a prescription. The drug’s manufacturer, Teva Pharmaceuticals, has not yet released the product’s price or its date of availability. More than 130 Americans die every day from opioid overdoses and the epidemic was responsible for over 47,600 American deaths in 2017.Researchers from Florida International University's Herbert Wertheim College of Medicine have discovered a new arsenic-based, broad-spectrum antibiotic that contains arsenic, Science Daily reported. The antibiotic, arsinothricin (AST), is naturally produced by soil bacteria and was found to be effective against a variety of bacteria. Although arsenic can be dangerous, AST toxicity tests were found not to kill human cells in tissue culture. The CDC has previously calculated that close to 2 million individuals in the United States are infected with drug-resistant bacteria each year which are responsible for causing nearly 23,000 annual deaths.
Urticaria Diagnosis Challenged by Overlapping Pruritic Skin Conditions
April 23rd 2025Urticaria is complicated to diagnose by its symptomatic overlap with other skin conditions and the frequent misclassification in literature of distinct pathologies like vasculitic urticaria and bullous pemphigus.
Read More
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
ACOs’ Focus on Rooting Out Fraud Aligns With CMS Vision Under Oz
April 23rd 2025Accountable care organizations (ACOs) are increasingly playing the role of data sleuths as they identify and report trends of anomalous billing in hopes of salvaging their shared savings. This mission dovetails with that of CMS, which under the new administration plans to prioritize rooting out fraud, waste, and abuse.
Read More